파이로젠 검사 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 용도별, 부문별 예측(2025-2030년)

Pyrogen Testing Market Size, Share & Trends Analysis Report By Product (Instruments, Consumables, Services), By Test Type (LAL Test, In Vitro Pyrogen Test, Rabbit Test), By End-use, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

파이로젠 검사 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 파이로젠 검사 시장 규모는 2030년까지 24억 9,000만 달러에 달할 것으로 예측되고 있습니다.

이 시장은 2025-2030년에 걸쳐 CAGR 11.2%로 성장할 것으로 예측됩니다. 의약품, 바이오 의약품, 생물제제를 포함한 치료 수요 증가가 예측 기간 동안 시장 성장을 가속하는 주요 요인입니다. 그리고 발열을 일으키는 유독한 분자 물질입니다. 파이로젠 검사는 제약, 바이오 의약품, 생명 공학, 의료기기 기업이 파이로젠이 없는지 확인하는 데 사용됩니다. 따라서 두 회사는 제품의 품질을 보장하기 위해 LAL, 체외 발열체, 토끼 검사 등 다양한 방법을 사용합니다.

만성 질환의 유병률 증가는 시장 성장을 지원하는 또 다른 주요 요인입니다. 만성 질환의 유병률은 선진국에서는 매우 높으며 중국과 인도를 포함한 신흥 국가에서도 높은 페이스로 증가하고 있습니다. 만성 호흡기 질환 등의 만성 질환의 발생으로 이어지고 있습니다. 따라서, 이러한 질환의 치료를 위한 치료나 의료기기에 대한 수요가 높아지고 있어, 그 결과, 의약품이나 의료기기를 포함한 제품의 품질을 보증하기 위한 파이로젠 검사에 대한 수요가 높아질 것으로 예측됩니다.

파이로젠 검사 시장 보고서 하이라이트

• 파이로젠 검사 키트 및 시약의 대규모 용도과 그 반복 구입에 의해 소모품은 2024년에 이 시장에서 최대의 수익을 올리는 부문이었습니다.
• 시장 세분화는 의약품, 생물제제, 치료 및 진단용 의료기기 수요가 높아짐에 따라 2024년에 현저한 점유율을 차지했습니다.
• 제약 및 바이오테크놀러지 기업 부문은 치료의 대량 생산과 의약품 개발을 위한 기업에 의한 연구 개발 투자 증가에 의해 2024년의 수익으로 파이로젠 검사 시장을 독점했습니다.
• 북미는 주요 지역 시장이며, 2024년에 최대의 수익 점유율을 차지했지만, 이것은 주로 이 지역에 의약품이나 의료기기를 포함한 다수의 의료 기업이 존재하기 때문입니다.
• 아시아태평양은 조사기간 중 가장 급성장하는 시장으로 예측되고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 파이로젠 검사 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련, 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 파이로젠 검사 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 가격 분석

제4장 파이로젠 검사 시장 : 제품별, 추정 및 예측 분석

• 제품 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 세계의 파이로젠 검사 시장 :제품별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 소모품
  • 기기
  • 서비스

제5장 파이로젠 검사 시장 : 검사 유형별, 추정 및 예측 분석

• 검사 유형 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 세계의 파이로젠 검사 시장 : 검사 유형별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • LAL 테스트
  • 검사관내 파이로젠 검사
  • 토끼 테스트

제6장 파이로젠 검사 시장 : 최종 용도별, 추정 및 예측 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 세계의 파이로젠 검사 시장 : 최종 용도별 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 제약 및 바이오테크놀러지 기업
  • 의료기기 기업
  • 기타

제7장 파이로젠 검사 시장 : 지역별, 추정 및 예측 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측, 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업, 경쟁의 분류
• 벤더 상황
  • 주요 리셀러와 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석, 2024년
• 기업 프로파일
  • Charles River Laboratories
  • Novo Nordisk
  • Merck KGaA
  • GenScript
  • bioMerieux SA
  • Lonza
  • Thermo Fisher Scientific, Inc.
  • Seikagaku Biobusiness Corporation
  • FUJIFILM Wako Chemicals USA Corporation(Pyrostar)
  • MiCAN Technologies Inc.

SHW

영문 목차

영문목차

Pyrogen Testing Market Growth & Trends:

The global pyrogen testing market size is anticipated to reach USD 2.49 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.2% from 2025 to 2030. Increasing demand for therapeutic drugs including pharmaceuticals, biopharmaceuticals, and biologics is the major factor that propels the growth of the market during the forecast period. Pyrogen is a toxic molecular substance that causes fever if induced in an animal or human body. Pyrogen testing is used by pharmaceutical, biopharmaceuticals, biotechnology, and medical devices companies to confirm the absence of pyrogen. Thus, the companies use various methods such as LAL, in vitro pyrogen, and rabbit test to ensure the quality of products.

Increasing prevalence of chronic diseases is another foremost factor supporting market growth. The prevalence of chronic diseases is very high in developed countries and is growing at a high pace in developing countries including China and India. Different factors such as unhealthy diet, smoking, alcohol consumption, and lack of exercise lead to the occurrence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases. Hence, there is a growing demand for therapeutic drugs and medical devices for the treatment of such diseases, which in turn is projected to fuel the demand for pyrogen testing to ensure the quality of products including drugs and devices.

Pyrogen Testing Market Report Highlights:

• Consumables was the largest revenue grossing segment of this market in 2024, owing to the large application of pyrogen testing kits and reagents along with its repetitive purchase.
• Instruments segment accounted for the remarkable share in the market in 2024 and is also expected to showcase significant growth during the forecast period, owing to rising demand for pharmaceutical, biologics, and medical devices for treatment and diagnosis.
• The pharmaceutical and biotechnology companies segment dominated the pyrogen testing market in terms of revenue in 2024, due to the large production of therapeutic drugs and growing investment in R&D by companies for drug development.
• North America is the leading regional market and accounted for the largest revenue share in 2024 primarily due to the existence of a large number of healthcare companies including pharmaceuticals and medical devices in this region.
• The Asia Pacific region is anticipated to be the fastest-growing market during the study period. The growing prevalence rate of chronic diseases in Asian countries including India and China is a major factor contributing to the expansion of the market in this region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Test Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Test type outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pyrogen Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising demand for therapeutic drugs
    • 3.2.1.2. Growing investment in R&D
    • 3.2.1.3. Increasing prevalence of chronic disease
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Stringent government regulations
• 3.3. Pyrogen Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Pyrogen Testing Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Pyrogen Testing Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Consumables
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Instruments
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Services
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pyrogen Testing Market: Test Type Estimates & Trend Analysis

• 5.1. Test Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Pyrogen Testing Market by Test Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. LAL test
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Chromogenic test
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)(Number of tests in thousands)
    • 5.4.1.3. Turbidimetric test
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)(Number of tests in thousands)
    • 5.4.1.4. Gel clot test
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)(Number of tests in thousands)
  • 5.4.2. In vitro pyrogen test
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)(Number of tests in thousands)
    • 5.4.2.2. Recombinant Factor C (rFC) testing
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)(Number of tests in thousands)
    • 5.4.2.3. Monocyte Activation Test (MAT)
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million) (Number of tests in thousands)
  • 5.4.3. Rabbit test
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)(Number of tests in thousands)

Chapter 6. Pyrogen Testing Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Pyrogen Testing Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Pharmaceutical & biotechnology companies
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Medical devices companies
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Others
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pyrogen Testing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Tests by Test Type in thousands)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Charles River Laboratories
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Novo Nordisk
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merck KGaA
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. GenScript
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. bioMerieux SA
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Lonza
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Thermo Fisher Scientific, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Seikagaku Biobusiness Corporation
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. FUJIFILM Wako Chemicals U.S.A. Corporation (Pyrostar)
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. MiCAN Technologies Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료